← Eichor
Condition: Hepatoma Resectable Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hepatoma Resectable

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235The Treatment of Bioartificial Liver With hiHep Cells After Extensive Hepatectomy
EARLY_Phase 1 · 1 location(s) · Sir Run Run Shaw Hospital · NCT05035108Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC
Phase 2 · 12 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT07018947Neoadjuvant Therapy of Iparomlimab and Tuvonralimab Combined With Lenvatinib for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT07014150A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
Phase 4 · 1 location(s) · The First Affiliated Hospital of Zhengzhou University · NCT06930573Y-90 SIRT for Unresectable HCC Larger Than 7cm
Phase 2 · 2 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06707233TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Out
Phase 2 · 58 location(s) · National Cancer Institute (NCI) · NCT06050252Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Phase 2 · 7 location(s) · Center Eugene Marquis · NCT05265208Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
NA · 1 location(s) · RWTH Aachen University · NCT04996914Intravital Microscopy in Human Solid Tumors
NA · 1 location(s) · Mayo Clinic · NCT03823144Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Bea
NA · 1 location(s) · The University of Hong Kong · NCT07305428Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
Phase N/A · 7 location(s) · Zhujiang Hospital · NCT06157060Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017Durvalumab and Tremelimumab in Resectable HCC
Phase 2 · 3 location(s) · University Health Network, Toronto · NCT05440864FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
Phase N/A · 4 location(s) · Fujian Provincial Hospital · NCT06561399Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05985798Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Phase 2 · 1 location(s) · Yongyi Zeng · NCT06349317Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Wei Zhang · NCT07154082Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT04615143Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma
Phase 1/Phase 2 · 2 location(s) · Zhejiang Cancer Hospital · NCT06741020Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular
Phase 2 · 3 location(s) · Enrico De Toni · NCT05844046Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06904183Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)
NA · 10 location(s) · Terumo Europe N.V. · NCT05911633Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397222
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.